WEKO3
アイテム
Two-fraction carbon ion radiotherapy for hepatocellular carcinoma: Preliminary results of a phase I/II clinical trial
https://repo.qst.go.jp/records/68309
https://repo.qst.go.jp/records/683092f174f1c-efa0-4ec7-97e2-81c1af9fb54b
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2006-01-30 | |||||
| タイトル | ||||||
| タイトル | Two-fraction carbon ion radiotherapy for hepatocellular carcinoma: Preliminary results of a phase I/II clinical trial | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Katou, Hirotoshi
× Katou, Hirotoshi× Yamada, Shigeru× Yasuda, Shigeo× Maeda, Yukiteru× Kamada, Tadashi× Mizoe, Junetsu× Ootou, Masao× Tsujii, Hirohiko× 加藤 博敏× 山田 滋× 安田 茂雄× 前田 幸輝× 鎌田 正× 溝江 純悦× 大藤 正雄× 辻井 博彦 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Introduction: We reported that the 4-fraction/1-week carbon ion radiotherapy (CIRT) appeared to be safe and to have a promising potential as a new, radical, and minimally invasive therapeutic option for hepatocellular carcinoma (HCC) at the 2004 ASCO annual meeting. In order to evaluate the safety and efficacy of 2-fraction/2-day CIRT, the next clinical trial was conducted within a phase I/II study between April 2003 and August 2005. Methods: The subjects of this report were 32 patients with follow-up period of over 6 months. CIRT was administered in doses of 32.0 to 38.8 cobalt gray equivalent (GyE) in 2 fractions for 2 days in a step-wise dose-escalation study. The median age was 68 (53-80) years. All patients had chronic liver diseases of Child-Pugh grade A in 30 or B in 2. Nine patients had intrahepatic recurrent lesions. The median tumor size was 4.7 (2.0-6.0) cm in diameter. Because no evaluation criteria are available for general hepatic toxicity in the impaired liver, the General Hepatic Toxicity Criteria based on NCI-CTC was defined by the Liver Cancer Working Group. Results: During a median follow-up of 18 (6-28) months, no treatment-related death occurred. Grade 3 hepatic toxicity according to NCI-CTC was observed in one patient in serum-GOT, GPT, T.BIL, and prothrombin activity. Grade 3 general hepatic toxicity occurred in the same one. No other Grade 3 or worse adverse events have occurred. The overall tumor response rate was 91% (29/32) at 6 months after the therapy. One-year and 1.5-year local control rate was 96% (23/24) and 88% (15/17), respectively. One-year and 1.5-year overall survival rate was 100% (24/24) and 94% (17/18), respectively. There were preliminarily no differences in results between the 2-fraction and 4-fraction CIRT. Conclusion: Two-fraction CIRT for HCC appears preliminarily safe and effective as well as the 4-fraction one. However, further observation is needed because the follow-up period is too short to confirm its clinical efficacy. |
|||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 2006 Gastrointestinal Cancers Symposium | |||||
| 発表年月日 | ||||||
| 日付 | 2006-01-28 | |||||
| 日付タイプ | Issued | |||||
